Oral probenecid cuts time to viral clearance in COVID-19
Aug 01, 2023
The median time to viral clearance was significantly shorter for 500 and 1,000 mg probenecid versus placebo.
FDA approves topical treatment for molluscum contagiosum
Jul 24, 2023
Ycanth has been approved for adults and children older than 2 years.
Lower frequency of social contact linked to lower total brain volume
Jul 13, 2023
“These results suggest that providing support for people to help them start and maintain their connections to others may be beneficial for preventing brain atrophy and the development of dementia,”...
FDA gives full approval to Alzheimer’s disease drug Leqembi
Jul 06, 2023
Although Leqembi did help reduce mental decline compared with placebo, the drug has been linked to two deaths from brain bleeds.
COVID-19 plus heart attack tied to higher mortality and complications
Jun 13, 2023
Further, significant racial disparities were seen in acute myocardial outcomes during the pandemic.
Incident MI tied to faster declines in cognitive function over time
Jun 05, 2023
Incident myocardial infarction is not associated with a decrease in global cognition, memory or executive function but is associated with faster declines in those measures over time.
Medicare will cover new class of Alzheimer’s drugs if fully approved by FDA, with limits
Jun 02, 2023
Drug makers also will have to gather and keep data in a registry showing how the drugs are working in the real world.
FDA grants full approval to Paxlovid to treat COVID-19
May 25, 2023
Paxlovid has been taken by older adults and others at high risk for severe COVID-19 under an emergency use approval.
Biden nominates head of National Cancer Institute to run NIH
May 15, 2023
The new director will face potential scrutiny from both Republicans and Democrats.
FDA approves first drug meant to ease Alzheimer’s disease-llnked agitation
May 11, 2023
Patients who received 2 or 3 mg of Rexulti had significant improvements in agitation scores compared with patients taking a placebo.